Preclinical and Clinical Evidence Supporting Use of Cannabidiol in Psychiatry Gioacchino Calapai, Carmen Mannucci, Ioanna Chinou, Luigi Cardia, Fabrizio Calapai, Emanuela Elisa Sorbara, Bernardo Firenzuoli, Valdo Ricca, Gian Franco Gensini and Fabio Firenzuoli Hindawi - Evidence-Based Complementary and Alternative Medicine, 2019, Article ID 2509129, 11 pages https://doi.org/10.1155/2019/2509129 Background : Cannabidiol (CBD) is a major chemical compound present in Cannabis sativa. CBD is a nonpsychotomimetic substance, and it is considered one of the most promising candidates for the treatment of psychiatric disorders. Objective. &e aim of this review is to illustrate the state of art about scientific research and the evidence of effectiveness of CBD [...]
Lire la suiteNeuroanatomical substrates involved in cannabinoid modulation of defensive responses F.A. Moreira, D.C. Aguiar, L.B. Resstel, S.F. Lisboa, A.C. Campos, F.V. Gomes and F.S. Guimaraes Journal of Psychopharmacology, 2012, 26, (1), 40–55 DOI: 10.1177/0269881111400651 Abstract Administration of Cannabis sativa derivatives causes anxiolytic or anxiogenic effects in humans and laboratory animals, depending on the specific compound and dosage used. In agreement with these findings, several studies in the last decade have indicated that the endocannabinoid system modulates neuronal activity in areas involved in defensive responses. The mechanisms of these effects, however, are still not clear. The present review summarizes recent data suggesting that they involve modulation of [...]
Lire la suiteIs cannabidiol an effective treatment for schizophrenia? R. Guinguis, M.I. Ruiz, G. Rada Medwave, 2017, 17, 7, e7010 DOI: 10.5867/medwave.2017.07.7010 Abstract Cannabidiol has recently been proposed as an antipsychotic for schizophrenia. However, its clinical use and safety is controversial. To answer this question, we used Epistemonikos, the largest database of systematic reviews in health, which is maintained by screening multiple information sources, including MEDLINE, EMBASE, Cochrane, among others. We identified six systematic reviews incorporating four primary studies overall, including two randomized trials. We extracted data from the systematic reviews, reanalyzed data from primary studies, conducted a meta-analysis and generated a summary of findings table [...]
Lire la suiteNotes from the Field : Acute Poisonings from a Synthetic Cannabinoid Sold as Cannabidiol — Utah, 2017–2018 Roberta Z. Horth, Barbara Crouch, B. Zane Horowitz, Amelia Prebish, Matthew Slawson, Jennifer McNair, Chris Elsholz, Stephen Gilley, Jenny Robertson, Ilene Risk, Mary Hill, Linnea Fletcher, Wei Hou, Dallin Peterson, Karlee Adams, Dagmar Vitek, Allyn Nakashima, Angela Dunn MMWR / May 25, 2018 / Vol. 67 / No. 20 US Department of Health and Human Services/Centers for Disease Control and Prevention On December 8, 2017, the Utah Poison Control Center (UPCC) notified the Utah Department of Health (UDOH) of reports of emergency department visits associated with reported [...]
Lire la suiteLabeling Accuracy of Cannabidiol Extracts Sold Online Marcel O. Bonn-Miller, Mallory J.E. Loflin, Brian F. Thomas, Jahan P. Marcu, Travis Hyke, Ryan Vandrey JAMA, 2017, Nov 7, 318, (17), 1708–1709. doi: 10.1001/jama.2017.11909 This study compares ingredients listed on the labels of cannabidiol products sold online to actual product constituents determined by laboratory analysis. There is growing consumer demand for cannabidiol (CBD), a constituent of the cannabis plant, due to its purported medicinal benefits for myriad health conditions. Viscous plant-derived extracts, suspended in oil, alcohol (tincture), or vaporization liquid, represent most of the retail market for CBD. Discrepancies between federal and state cannabis laws have resulted in [...]
Lire la suiteTrends in Internet Searches for Cannabidiol (CBD) in the United States Eric C. Leas, Alicia L. Nobles, PhD, Theodore L. Caputi, Mark Dredze, DaveyM. Smith, JohnW. Ayers JAMA Network Open, 2019, 2, (10), e1913853. doi: 10.1001/jamanetworkopen.2019.13853 Introduction Cannabidiol (CBD) is widely promoted as a panacea. For example, the cannabis brand MedMen claims CBD treats acne, anxiety, opioid addiction, pain, and menstrual problems.1 However, the US Food and Drug Administration has only approved highly purified CBD (Epidiolex) for treating epilepsy. To our knowledge, there is currently no population-focused surveillance of public interest in CBD. Consequently, many question whether CBD should be prioritized by public health leaders [...]
Lire la suitePsychiatric Comorbidity of Cannabis Use Disorder David Gorelick In book : "Cannabis Use Disorders", January 2019 DOI : 10.1007/978-3-319-90365-1_13 Abstract : Objective : This chapter reviews the epidemiology and treatment of cannabis use disorder (CUD) with psychiatric comorbidity. Methods : We summarize the findings of English-language epidemiological studies reporting current (past-year) comorbidity and of controlled clinical trials of treatment in which the majority of participants had diagnosed CUD and a specific comorbid disorder. Results : There is substantial CUD comorbidity among community-dwelling adults with major psychiatric disorders: 4–6% for depression, 14% for bipolar disorder, 5% for anxiety disorder, and 16% for schizophrenia. Conversely, there is substantial psychiatric [...]
Lire la suiteEndocannabinoid System in Neurological Disorders (Endocannabinoid System and Neurodegeneration) Roberta Ranieri, Chiara Laezza, Maurizio Bifulco, Daniela Marasco and Anna Maria Malfitano Recent Patents on CNS Drug Discovery, 2015, Vol. 10, No. 2, 24 p. Abstract : Background : Several studies support the evidence that the endocannabinoid system and cannabimimetic drugs might have therapeutic potential in numerous pathologies. These pathologies range from neurological disorders, atherosclerosis, stroke, cancer to obesity/metabolic syndrome and others. Methods : In this paper we review the endocannabinoid system signaling and its alteration in neurodegenerative disorders like multiple sclerosis, Alzheimer’s disease, Parkinson’s disease and Huntington’s disease and discuss the main findings about the use [...]
Lire la suiteEndocannabinoid System Aleksandra Tarasiuka, Maciej Salagaa, and Jakub Fichna, Medical University of Lodz, Lodz, Poland Encyclopedia of Gastroenterology, 2nd Edition © 2019 Elsevier Inc. All rights reserved. https://doi.org/10.1016/B978-0-12-801238-3.65635-0 Introduction 1 Cannabinoids and Their Role in the Physiological and Pathophysiological Processes in the GI Tract 3 Physiological Conditions 3 Gut motility 3 Gastric secretion and emptying 3 Pathophysiological Conditions 4 IBS 4 IBD 5 Colon cancer 5 Peptic ulcer disease 5 Endocannabinoid System and Its Interplay With Other Systems 5 Cholecystokinin 5 Endovanilloids 6 Opioids 6 Endocannabinoid System and Gut Microbiota 6 Conclusion 7 Acknowledgments 7 References Introduction Endocannabinoid system (ECS) is one of the crucial physiological systems that may be targeted to improve human health. Endocannabinoids and their receptors are localized in various organs [...]
Lire la suitePlastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders Alline C. Campos, Manoela V. Fogaça, Franciele F. Scarante, Sâmia R. L. Joca, Amanda J. Sales, Felipe V. Gomes, Andreza B. Sonego, Naielly S. Rodrigues, Ismael Galve-Roperh, and Francisco S. Guimarães Frontiers in Pharmacology, 2017. doi: 10.3389/fphar.2017.00269 Beneficial effects of cannabidiol (CBD) have been described for a wide range of psychiatric disorders, including anxiety, psychosis, and depression. The mechanisms responsible for these effects, however, are still poorly understood. Similar to clinical antidepressant or atypical antipsychotic drugs, recent findings clearly indicate that CBD, either acutely or repeatedly administered, induces plastic changes. [...]
Lire la suite